File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells

TitleGastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells
Authors
Issue Date2005
Citation
Neoplasia, 2005, v. 7 n. 4, p. 426-431 How to Cite?
AbstractGastrin-releasing peptide receptor (GRPR) and the epidermal growth factor receptor (EGFR) are expressed in several cancers including non-small cell lung cancer (NSCLC). Here we demonstrate the activation of EGFR by the GRPR ligand, gastrin-releasing peptide (GRP), in NSCLC cells. GRP induced rapid activation of p44/42 MAPK in lung cancer cells through EGFR. GRP-mediated activation of MAPK in NSCLC cells was abrogated by pretreatment with the anti-EGFR-neutralizing antibody, C225. Pretreatment of NSCLC cells with neutralizing antibodies to the EGFR ligands, TGF-α or HB-EGF, also decreased GRP-mediated MAPK activation. On matrix metalloproteinase (MMP) inhibition, GRP failed to activate MAPK in NSCLC cells. EGF and GRP both stimulated NSCLC proliferation, and inhibition of either EGFR or GRPR resulted in cell death. Combining a GRPR antagonist with the EGFR tyrosine kinase inhibitor, gefitinib, resulted in additive cytotoxic effects. Additive effects were seen at gefitinib concentrations from 1 to 18 μM, encompassing the ID50 values of both gefitinib-sensitive and gefitinib-resistant NSCLC cell lines. Because a major effect of GRPR appears to be promoting the release of EGFR ligand, this study suggests that a greater inhibition of cell proliferation may occur by abrogating EGFR ligand release in consort with inhibition of EGFR. Copyright © 2005 Neoplasia Press, Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/194145
ISSN
2014 Impact Factor: 4.252
2015 SCImago Journal Rankings: 2.541
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorThomas, SM-
dc.contributor.authorGrandis, JR-
dc.contributor.authorWentzel, AL-
dc.contributor.authorGooding, WE-
dc.contributor.authorLui, VWY-
dc.contributor.authorSiegfried, JM-
dc.date.accessioned2014-01-30T03:32:13Z-
dc.date.available2014-01-30T03:32:13Z-
dc.date.issued2005-
dc.identifier.citationNeoplasia, 2005, v. 7 n. 4, p. 426-431-
dc.identifier.issn1522-8002-
dc.identifier.urihttp://hdl.handle.net/10722/194145-
dc.description.abstractGastrin-releasing peptide receptor (GRPR) and the epidermal growth factor receptor (EGFR) are expressed in several cancers including non-small cell lung cancer (NSCLC). Here we demonstrate the activation of EGFR by the GRPR ligand, gastrin-releasing peptide (GRP), in NSCLC cells. GRP induced rapid activation of p44/42 MAPK in lung cancer cells through EGFR. GRP-mediated activation of MAPK in NSCLC cells was abrogated by pretreatment with the anti-EGFR-neutralizing antibody, C225. Pretreatment of NSCLC cells with neutralizing antibodies to the EGFR ligands, TGF-α or HB-EGF, also decreased GRP-mediated MAPK activation. On matrix metalloproteinase (MMP) inhibition, GRP failed to activate MAPK in NSCLC cells. EGF and GRP both stimulated NSCLC proliferation, and inhibition of either EGFR or GRPR resulted in cell death. Combining a GRPR antagonist with the EGFR tyrosine kinase inhibitor, gefitinib, resulted in additive cytotoxic effects. Additive effects were seen at gefitinib concentrations from 1 to 18 μM, encompassing the ID50 values of both gefitinib-sensitive and gefitinib-resistant NSCLC cell lines. Because a major effect of GRPR appears to be promoting the release of EGFR ligand, this study suggests that a greater inhibition of cell proliferation may occur by abrogating EGFR ligand release in consort with inhibition of EGFR. Copyright © 2005 Neoplasia Press, Inc. All rights reserved.-
dc.languageeng-
dc.relation.ispartofNeoplasia-
dc.titleGastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1593/neo.04454-
dc.identifier.pmid15967120-
dc.identifier.scopuseid_2-s2.0-18644367044-
dc.identifier.volume7-
dc.identifier.issue4-
dc.identifier.spage426-
dc.identifier.epage431-
dc.identifier.isiWOS:000229011600014-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats